Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization
Complement activation plays a significant role in age-related macular degeneration (AMD) pathogenesis, and polymorphisms interfering with factor H (fH) function, a complement alternative pathway (AP) inhibitor, are associated with increased AMD risk. We have previously validated an AP inhibitor, a f...
Main Authors: | Gloriane Schnabolk, Nathaniel Parsons, Elisabeth Obert, Balasubramaniam Annamalai, Cecile Nasarre, Stephen Tomlinson, Alfred S. Lewin, Bärbel Rohrer |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-06-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117301195 |
Similar Items
-
Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy
by: Anne Louise Askou, et al.
Published: (2019-06-01) -
Mechanisms of FH Protection Against Neovascular AMD
by: Céline Borras, et al.
Published: (2020-04-01) -
Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization
by: Sook Hyun Chung, et al.
Published: (2020-06-01) -
Choroidal neovascular membrane
by: Bhatt Nitul, et al.
Published: (1998-01-01) -
AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization
by: Chris P. Hughes, et al.
Published: (2019-06-01)